HM Hospitales and ERESA have acquired focal ultrasound (HIFU) treatment equipment, located in HM CINAC, integrated in the Hospital Universitario HM Puerta del Sur. With this acquisition, this centre has become one of the few European centres where this treatment is available. In fact, Spain is the second European country, after Switzerland, to have a HIFU.
Using this ultrasound technique and with magnetic resonance imaging diagnoses (only compatible with 3T Magnetic Resonance), this process consists of applying an ultrasound treatment over a target of only a few millimetres that generates localised hyperthermia and finally, ablation of the targeted area.
The General Director of HM Hospitales, Dr. Juan Abarca, points out that acquiring the HIFU along with ERESA makes them a pioneer in Spain in the use of the newest techniques, always to the benefit of the patients: “The HIFU is the first system in Spain designed for treating neurofunctional disorders. The acquisition of the HIFU along with the PET-Magnetic Resonance machine makes HM CINAC a great tool of study and treatment, thereby increasing the clinical and basic research and therapeutic capabilities of this Centre of Neurosciences, where best efforts are made into becoming a leading benchmark in the diagnosis and treatment of neurodegenerative and neuropsychiatric diseases”.
For her part, the ERESA CEO Marta Saus Cano, declares that ERESA’s priority is to work on improving the population’s health by boosting projects that involve innovation, contribute an added differentiating value and have the potential to improve people’s lives. “This is why, together with HM Hospitales we are going to put in place a pioneering technique that is not invasive, that has effective results and that minimises the risks and side effects inherent in some of the current therapeutic options available, whilst also managing to reduce health costs”, she adds.
About the HIFU
The HIFU is indicated for patients suffering from essential tremor, although its main application in the near future will be treatment of Parkinson’s disease and other neuropsychiatric and neurofunctional disorders.
One of the main advantages of this treatment is that it does not require any form of intracranial intervention. During the treatment, the doctors can see if the target and effect are appropriate, whilst also making corrections to improve the effectiveness and reduce the adverse effects before proceeding with the focal ablation of tissue.